JBF Capital’s Pacific Biosciences PACB Stock Holding History

JBF Capital’s Portfolio PACB Stock Details PACB Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2019 Q4	–	Sell	-15,000	Closed	-$77K	–	86
2019 Q3	$77K	Buy	+15,000	New	+$83.9K	0.01%	70

Other funds holding PACB

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

AQR Arbitrage Greenwich, Connecticut $6.09B AUM 27.01% 1-Year Est. Return

Magnetar Financial Evanston, Illinois $9.84B AUM 190.64% 1-Year Est. Return

Bellevue Group Kuesnacht, Switzerland $4.2B AUM 54.85% 1-Year Est. Return

Capital International Investors Los Angeles, California $427B AUM 29.17% 1-Year Est. Return

WIC

Water Island Capital New York $896M AUM 107.59% 1-Year Est. Return

GCM

Glenview Capital Management New York $3.98B AUM 20.52% 1-Year Est. Return

ACH

ArrowMark Colorado Holdings Denver, Colorado $3.76B AUM 21.77% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

JBF Capital's PACB Position: Q4 2019 in Review

JBF Capital sold out of Pacific Biosciences (PACB) in Q4 2019, closing a stake of 15,000 shares — an estimated $77K sold.

JBF Capital first reported a position in PACB in Q3 2019 and held it in 1 quarter. The position peaked at $77K in Q3 2019. 143 funds tracked by Wall St. Rank hold PACB as of Q4 2019.

JBF Capital reported no remaining Pacific Biosciences position as of Q4 2019 after selling out during the quarter.
JBF Capital sold 15,000 Pacific Biosciences shares in Q4 2019, an estimated $77K.
JBF Capital first reported a position in Pacific Biosciences in Q3 2019 and held it in 1 quarter.
JBF Capital's Pacific Biosciences position peaked at $77K in Q3 2019.
143 funds tracked by Wall St. Rank held Pacific Biosciences as of Q4 2019.

Based on JBF Capital's 13F filing for Q4 2019, filed 14 Feb 2020.